Investors should monitor upcoming catalysts: completion of BASECAMP enrollment in Q3 2026 and top-line data in Q4 2026. The TRAILHEAD expansion into the U.S. and Australia, along with FSHD preclinical validation, could broaden SAT-3247's market potential. The financing avoids near-term dilution risk.
Price Chart
Executive Summary
Satellos Bioscience reported its 2025 financial results and highlighted significant clinical progress, including the initiation of its Phase 2 BASECAMP trial for SAT-3247 in pediatric Duchenne muscular dystrophy (DMD) patients and positive interim functional data from the TRAILHEAD trial in adults. The company also secured $57.2 million in equity financing and began Nasdaq trading under MSLE, extending its cash runway into 2027.
Key Facts
- Completed $57.2 million equity financing on Feb. 9, 2026, strengthening balance sheet
- Initiated BASECAMP, a global placebo-controlled Phase 2 trial of SAT-3247 in pediatric DMD patients; first patient dosed Feb. 12, 2026
- Presented TRAILHEAD trial data showing maintained or improved grip strength over 9–13 months in four adult DMD patients
- Cash and short-term investments: $27.7 million as of Dec. 31, 2025 (down from $48.5 million in 2024 due to clinical spending)
- Net loss for 2025: $24.9 million, up from $20.6 million in 2024, driven by increased R&D and G&A expenses
- R&D expenses rose to $18.4 million (from $14.4 million) due to Phase 2 trial initiation
- Cash runway now expected through 2027, post-financing
- Presented new preclinical data showing significant muscle strength enhancement in FSHD model, expanding SAT-3247's potential beyond DMD
Financial Impact
The $57.2 million gross proceeds significantly improve liquidity and extend operational runway. Increased R&D spend ($18.4M) reflects advancing clinical development, while net loss widened to $24.9M. No revenue generated as company remains pre-revenue.
Risk Factors
- Clinical trial results may not replicate prior functional improvements, especially in larger, placebo-controlled BASECAMP study
- Small patient cohorts (e.g., n=4 in TRAILHEAD) limit statistical power
- High R&D burn rate increases dependence on future financing if milestones are delayed
- Forward-looking statements dominate; actual outcomes may differ materially
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001171843-26-001965 |
| Document: f6k_032726.htm | 0001171843-26-001965 |
| Document: 0001171843-26-001965-index-headers.html | 0001171843-26-001965 |
| Document: 0001171843-26-001965-index.html | 0001171843-26-001965 |
| Document: 0001171843-26-001965.txt | 0001171843-26-001965 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | 6-K | $6.42 | awaiting T+20 | — | $6.88 (+7.17%) |
Oct 21, 2026 6d ago | 6-K | $6.70 | awaiting T+20 | — | $6.88 (+2.69%) |
Oct 5, 2026 22d ago | 6-K | $8.05 | awaiting T+20 | — | $6.88 (−14.53%) |
Sep 30, 2026 27d ago | 6-K | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 30, 2026 27d ago | Press Release | $8.50 | awaiting T+20 | — | $6.88 (−19.06%) |
Sep 24, 2026 4w ago | 6-K | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 24, 2026 4w ago | Press Release | $8.71 $6.63 | ▼ −23.94% | ▼ −23.52% | $6.88 (−21.01%) |
Sep 15, 2026 6w ago | 6-K | $9.36 $7.04 | ▼ −24.79% | ▼ −27.51% | $6.88 (−26.50%) |
Sep 9, 2026 6w ago | 6-K | $10.02 $7.63 | ▼ −23.85% | ▼ −26.05% | $6.88 (−31.34%) |
Sep 1, 2026 8w ago | 6-K | $9.08 $8.69 | ▼ −4.30% | ▼ −5.48% | $6.88 (−24.23%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers